Anti-Obesity Drugs Market to Grow at a CAGR of 43.72% During 2024-2032, Aided by the Rising Obesity Rates Across the 8 Major Markets

Anti-Obesity Drugs Market Overview

Anti-obesity drugs are recommended for individuals with a body mass index (BMI) greater than 30 or people with a BMI more than 27 and having serious medical conditions (diabetes or high blood pressure) linked to obesity. These drugs help in reducing around 3% to 12% of the total body weight of the patient in a year. The rising incidence of obesity and the increasing focus on weight management are the primary drivers of the market. The surge in regulatory approvals of new anti-obesity drugs is anticipated to bolster the market demand. Moreover, the growing adoption of combination therapies, innovation in drug development, and rising awareness of obesity-related health risks are poised to influence the market dynamics in the forecast period.

Key Findings 

• A study released by the Lancet in 2022  revealed that one in eight people is affected by obesity, accounting for over 1 billion people in the world. Further, it was estimated that 43% of adults were overweight in 2022. The growing burden of obesity is bolstering the demand for anti-obesity drugs.
• In November 2023 , Eli Lilly and Company's anti-obesity drug Zepbound™ (tirzepatide) injection was cleared by the U.S. Food and Drug Administration (FDA), making it the first FDA-approved treatment that activates two incretin hormone receptors (GIP and GLP-1) to target an underlying cause of excess weight. The rise in such new drug approvals is a major market trend.
• The rising preference for pharmaceutical interventions for weight management and the expansion in treatment options are likely to elevate the market value in the coming years.

Anti-Obesity Drugs Market Demand Drivers

According to the NCD Risk Factor Collaboration (NCD-RisC),  over 1 billion people are living with obesity worldwide, comprising about 880 million adults and 159 million adolescents and children between the ages of 5 and 19 years. The World Obesity Federation also states that approximately 3 billion individuals are either overweight or obese, indicating the increasing risk of obesity in several countries in the world. This rising rate of obesity due to sedentary lifestyles, unhealthy eating habits, and genetic factors, is expected to fuel the market demand in the forecast period.

Anti-Obesity Drugs Market Segmentation Analysis

The Drug Type Segment Holds a Substantial Market Share

Based on the drug type, the market segmentation includes semaglutide, phentermine/topiramate, naltrexone/bupropion, liraglutide, gelesis 100, orlistat, phentermine, methamphetamine, tirzepatide, and others. Out of these, Semaglutide is one of the leading anti-obesity drugs in the market which can be attributed to its positive results in clinical trials, with the findings suggesting its efficacy in achieving significant reductions in body weight. On the other hand, the combination drug Phentermine/Topiramate includes phentermine, an appetite suppressant, and topiramate, an anticonvulsant that helps in weight loss by increasing feelings of fullness.

The market report also offers insights based on drug class, mechanism of action, prescription type, distribution channel, and region.

Anti-Obesity Drugs Market: Competitive Landscape

• In May 2024 , American pharmaceutical giant Eli Lilly and Company announced an additional investment of USD 5.3 billion in a new Indiana manufacturing, making the total investment to USD 9 billion. The investment is aimed at boosting the production of the active pharmaceutical ingredients (APIs) of its highly popular diabetes and weight loss drugs, Mounjaro and Zepbound.
• In March 2024 , California-based clinical-stage biotech firm Viking Therapeutics revealed positive data for its investigational weight loss tablet (VK2735), with the findings indicating that the drug reduced the weight of the participants by 3.3% in 28 days in a small early-stage trial.
• Other players involved in the market include GlaxoSmithKline PLC, Pfizer Inc., Novo Nordisk A/S, Rhythm Pharmaceuticals, KVK Tech Inc., Currax Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Vivus LLC, Gelesis Holding Inc., and Boehringer Ingelheim International GmbH.

Anti-Obesity Drugs Market Analysis by Region

The United States is Projected to Lead the Market Share

The market report offers insight into various geographical locations, including the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. The United States dominates the market share due to the high obesity rates and heightened awareness of obesity-related diseases, which propels the demand for anti-obesity medications. The market also benefits from the rising introduction of newer drugs and the presence of key market players. Further, the increasing disposable income and the growing demand for pharmaceutical interventions for weight management are expected to boost the market growth in the region.

Key Offerings of the Report

• The EMR report gives an overview of the global market for anti-obesity drugs for the time span of (2017-2023) and (2024-2032).
• The report also offers historical (2017-2023) and forecast (2024-2032) market information for the drug type, drug class, mechanism of action, prescription type, distribution channel, and region of the global market.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790